The global medical device contract manufacturing market is poised for substantial growth, with projections indicating it will reach $330.35 billion by 2036, up from $93.80 billion in 2025, according to a new report from Future Market Insights. This represents a compound annual growth rate (CAGR) of 12.1% over the forecast period. The expansion is driven by original equipment manufacturers (OEMs) increasingly outsourcing validated production, assembly, packaging, and quality-controlled manufacturing to specialized partners.
Contract manufacturers are evolving from capacity providers into strategic production partners, handling design transfer, process validation, cleanroom assembly, regulatory documentation, and launch-risk mitigation. Rising device complexity, stricter regulatory oversight, and demand for faster commercialization are pushing OEMs toward suppliers with established ISO 13485 quality systems and proven compliance capabilities.
Key growth drivers include OEMs outsourcing validated assembly to reduce capital expenditure and accelerate product launches, growing demand for cleanroom manufacturing for sterile implants and wearable devices, and increasing regulatory compliance requirements. Regionalized and nearshore supply chain strategies are reducing dependence on single-country sourcing. The U.S. Food and Drug Administration reported 30,120 registered medical device establishments in fiscal year 2024, highlighting the scale of regulated manufacturing networks.
Technology innovation is a primary differentiator, with advanced injection molding, micro-molding, additive manufacturing, and electronics integration enabling suppliers to address sophisticated device requirements. Investments in new-product-introduction (NPI) facilities and cleanroom infrastructure are evident, such as Flex’s healthcare NPI center near Boston and Sanmina’s expansion of an ISO 8 cleanroom facility in Ireland.
Despite strong growth, the market faces challenges including expensive supplier qualification, maintaining audit-ready documentation, and compliance with FDA, MDR, PMDA, MHRA, and NMPA regulations. Pricing pressure persists in commoditized segments like basic molding and assembly.
Finished devices are projected to dominate the service type segment with 38.0% market share in 2026, while Class II devices are expected to capture 46.0% of the market by device class. Cardiovascular applications will represent 24.0% of application revenue, and injection molding is expected to account for 31.0% of manufacturing revenue.
Regionally, India is projected to record the fastest growth with a CAGR of 14.2% through 2036, supported by government-backed medical device parks and production incentives. China follows with a 13.4% CAGR, while the United States remains the largest market, expanding from $35.0 billion in 2026 to $104.8 billion by 2036 at an 11.6% CAGR.
Competitive landscape is moderately concentrated, with leading companies including Jabil, Flex, Integer Holdings, Sanmina, TE Connectivity, Viant, Resonetics, Phillips Medisize, Gerresheimer, and Nolato. Competition centers on design-transfer capabilities, process validation expertise, and regulatory support. Recent strategic developments include Molex’s acquisition of Vectura Group for Phillips Medisize, Flex’s healthcare NPI center, and TE Connectivity’s new PROPELUS centers.
For more detailed market forecasts and competitive benchmarking, visit Future Market Insights.
This news story relied on content distributed by 24-7 Press Release. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Medical Device Contract Manufacturing Market to Reach $330.35 Billion by 2036 as OEMs Increase Outsourcing.